(Q45290079)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18625582%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

title

Animal welfare and the refinement of neuroscience research methods--a case study of Huntington's disease models (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18625582%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18625582%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Peter Sandøe

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18625582%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

author name string

Axel K Hansen

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18625582%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

language of work or name

1 reference

1 July 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18625582%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18625582%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

volume

42

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18625582%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18625582%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

page(s)

277-283

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18625582%20AND%20SRC:MED&resulttype=core&format=json

Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid

10 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1258%2FLA.2008.007147

Replicating Huntington's disease phenotype in experimental animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FLA.2008.007147

Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FLA.2008.007147

Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FLA.2008.007147

Experimental basis for the putative role of GluR6/kainate glutamate receptor subunit in Huntington's disease natural history

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FLA.2008.007147

Subacute systemic 3-nitropropionic acid intoxication induces a distinct motor disorder in adult C57Bl/6 mice: behavioural and histopathological characterisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FLA.2008.007147

Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FLA.2008.007147

Standardization and statistical approaches to therapeutic trials in the R6/2 mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FLA.2008.007147

Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FLA.2008.007147

Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FLA.2008.007147

The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FLA.2008.007147

Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FLA.2008.007147

Molecular and behavioral analysis of the R6/1 Huntington's disease transgenic mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FLA.2008.007147

Anti-inflammatory treatment with acetylsalicylate or rofecoxib is not neuroprotective in Huntington's disease transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FLA.2008.007147

Ethics and refinement in animal research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FLA.2008.007147

Progressive abnormalities in skeletal muscle and neuromuscular junctions of transgenic mice expressing the Huntington's disease mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FLA.2008.007147

Oral uridine pro-drug PN401 decreases neurodegeneration, behavioral impairment, weight loss and mortality in the 3-nitropropionic acid mitochondrial toxin model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FLA.2008.007147

The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FLA.2008.007147

Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FLA.2008.007147

Publications should include an animal-welfare section

21 January 2018

1 reference

https://api.crossref.org/works/10.1258%2FLA.2008.007147